Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111534 | 0.91 | SPHK1 (0.37) | SPHK1RARBSPHK2FFAR4 | |
| SCHEMBL10946817 | 0.86 | SPHK1 (0.47) | SPHK1RARBSPHK2FFAR4CYP3A4 | |
| SCHEMBL10946823 | 0.86 | SPHK1 (0.47) | SPHK1RARBSPHK2FFAR4CYP3A4 | |
| SCHEMBL9775763 | 0.85 | SPHK1 (0.48) | SPHK1RARBSPHK2FFAR4CYP3A4 | |
| SCHEMBL9775767 | 0.85 | SPHK1 (0.48) | SPHK1RARBSPHK2FFAR4CYP3A4 | |
| SCHEMBL10947243 | 0.84 | SPHK1 (0.43) | SPHK1RARBSPHK2FFAR4CYP3A4 | |
| SCHEMBL10947235 | 0.84 | SPHK1 (0.43) | SPHK1RARBSPHK2FFAR4CYP3A4 | |
| SCHEMBL10943958 | 0.83 | SPHK1 (0.42) | SPHK1RARBSPHK2CYP3A4CYP2C9 | |
| SCHEMBL10943945 | 0.83 | SPHK1 (0.42) | SPHK1RARBSPHK2CYP3A4CYP2C9 | |
| SCHEMBL20102577 | 0.82 | MEN1 (0.34) | SPHK1SPHK2FFAR4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | SPHK1 1401/4885RARB 1858/4885SPHK2 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.